Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
View Patent ↗Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
1. A method for inhibiting or reducing blood loss in a patient comprising administering to the patient a non-naturally occurring kallikrein inhibitor polypeptide in combination with an anti-fibrinolytic agent, wherein the kallikrein inhibitor polypeptide comprises the amino acid sequence Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Arg Ala Ala His Pro Arg Trp Phe Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp (amino acid residues 3-60 of SEQ ID NO:2),
wherein the non-naturally occurring kallikrein inhibitor polypeptide and the anti-fibrinolytic agent are administered in combination with an anticoagulation agent, and
wherein the blood loss is perioperative blood loss due to a surgical procedure performed on the patient.
2. The method of claim 1 , wherein the surgical procedure is a cardiothoracic surgery.
3. The method of claim 2 , wherein the cardiothoracic surgery is cardiopulmonary bypass or coronary artery bypass grafting.
4. The method of claim 1 , wherein the anti-fibrinolytic agent is selected from the group consisting of: tranexamic acid, epsilon amino caproic acid, aprotinin, Desmopressin, pirfenidone, and combinations thereof.
5. The method of claim 1 , wherein the anti-fibrinolytic agent is epsilon amino caproic acid.
6. The method of claim 1 , wherein the anti-fibrinolytic agent is aprotinin.
7. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.
8. The method of claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:2.
9. The method of claim 1 , wherein the polypeptide consists of amino acid residues 3-60 of SEQ ID NO:2.
10. The method of claim 1 , wherein the surgical procedure is selected from the group consisting of orthopedic surgery, hepatectomy, nephrectomy, and a procedure utilizing extracorporeal circulation or dialysis.
11. The method of claim 10 , wherein the surgical procedure is orthopedic surgery.
12. The method of claim 11 , wherein the orthopedic surgery is hip replacement surgery.
13. The method of claim 11 , wherein the orthopedic surgery is knee replacement surgery.
14. The method claim 11 , wherein the orthopedic surgery is bone fracture repair.
15. The method of claim 10 , wherein the surgical procedure is hepatectomy.
16. The method of claim 15 , wherein the hepatectomy is an orthotopic liver transplant.
17. The method of claim 10 , wherein the surgical procedure is nephrectomy.
18. The method of claim 10 , wherein the surgical procedure is a procedure utilizing extracorporeal circulation or dialysis.
19. The method of claim 2 , wherein the cardiothoracic surgery is pediatric cardiothoracic surgery.
20. The method of claim 2 , wherein the cardiothoracic surgery is lung transplantation.
21. The method of claim 1 , wherein the polypeptide and anti-fibrinolytic agent are administered prior to the surgical procedure.
22. The method of claim 1 , wherein said administering is performed intravenously.
23. The method of claim 1 , wherein the anticoagulation agent is selected from the group consisting of: heparin, warfarin, coumadin, dicumarol, phenprocoumon, acenocoumarol, ethyl biscoumacetate, hirudin, bivalirudin, a direct thrombin inhibitor, and an indandione derivative.
24. The method of claim 1 , wherein the non-naturally occurring kallikrein inhibitor polypeptide and the anti-fibrinolytic agent are administered in combination with an anti-platelet agent.
25. The method of claim 24 , wherein the anti-platelet agent is selected from the group consisting of: aspirin, thienopyridine, ticlopidine, clopidogrel, dipyridamole, sulfinpyrazone, and an RGD mimetic.
26. The method of claim 1 , wherein the non-naturally occurring kallikrein inhibitor polypeptide is administered at a dose of less than 20 mg.
27. The method of claim 1 , wherein the non-naturally occurring kallikrein inhibitor polypeptide is administered at a dose of less than 15 mg.
28. The method of claim 1 , wherein the non-naturally occurring kallikrein inhibitor polypeptide is administered at a dose of less than 10 mg.
29. The method of claim 1 , wherein the non-naturally occurring kallikrein inhibitor polypeptide is administered at a dose of less than 5 mg.